Sponsor hub

University of Oxford clinical trial failures

Review 30 stopped clinical trials from University of Oxford, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 1 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials30
Likely biological signals1
Shown below30

Dominant stop reasons

OPERATIONAL
15
OTHER/UNKNOWN
12
REGULATORY
2
SAFETY
1

Notable sponsors

University of Oxford
30

Related phases

Phase I
18
Phase II
7
Early Phase I
2
Phase III
1
Phase IV
1

Crawlable stopped-trial records

Open Explore

Showing up to 30 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05270265: Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine

Early Phase I Malaria, Vivax trial by University of Oxford. Stop reason: OPERATIONAL.

The study was terminated due to administrative delays in the approval of a substantial amendment to extend the shelf-life of Pvs25-IMX313. Regulatory approval was only received on 11 August 2023, after end of study visits had already been conducted.

NCT04984759: Tafenoquine and Primaquine in Colostrum and Breast Milk

Phase IV Healthy Lactating Women trial by University of Oxford. Stop reason: OPERATIONAL.

Local EC requested that the arms of study be submitted as separate protocols so they could respond to the different risk of each arm. In response investigators have withdrawn this protocol and begun separate submissions, starting with NCT06191458.